Neurobiology of Disease

The Role of G-Protein Receptor 84 in Experimental Neuropathic Pain

Louise S.C. Nicol, John M. Dawes, Federica La Russa, Athanasios Didangelos, Anna K. Clark, Clive Gentry, John Grist, John B. Davies, Marzia Malcangio, and Stephen B. McMahon

1Wolfson Centre for Age-Related Disease, King’s College London, London, SE1 1UL, United Kingdom, 2Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom, and 3GlaxoSmithKline, Harlow, CM19 5AW, United Kingdom

G-protein receptor 84 (GPR84) is an orphan receptor that is induced markedly in monocytes/macrophages and microglia during inflammation, but its pathophysiological function is unknown. Here, we investigate the role of GPR84 in a murine model of traumatic nerve injury. Naïve GPR84 knock-out (KO) mice exhibited normal behavioral responses to acute noxious stimuli, but subsequent to partial sciatic nerve ligation (PNL), KOs did not develop mechanical or thermal hypersensitivity, in contrast to wild-type (WT) littermates. Nerve injury increased ionized calcium binding adapter molecule 1 (Iba1) and phosphorylated p38 MAPK immunoreactivity in the dorsal horn and Iba1 and cluster of differentiation 45 expression in the sciatic nerve, with no difference between genotypes. PCR array analysis revealed that Gpr84 expression was upregulated in the spinal cord and sciatic nerve of WT mice. In addition, the expression of arginase-1, a marker for anti-inflammatory macrophages, was upregulated in KO sciatic nerve. Based on this evidence, we investigated whether peripheral macrophages behave differently in the absence of GPR84. We found that lipopolysaccharide-stimulated KO macrophages exhibited attenuated expression of several proinflammatory mediators, including IL-1β, IL-6, and TNF-α. Forskolin-stimulated KO macrophages also showed greater CAMP induction, a second messenger associated with immunosuppression. In summary, our results demonstrate that GPR84 is a proinflammatory receptor that contributes to nociceptive signaling via the modulation of macrophages, whereas in its absence the response of these cells to an inflammatory insult is impaired.

Key words: cytokine; G-protein linked receptors; inflammation; macrophage; microglia; neuropathic pain

Introduction

Although there has been significant progress in the understanding of pain processes, chronic pain remains an area of considerable unmet medical need because of limited number and efficacy of treatments. Therefore, the search for new and more effective treatment continues. It has emerged that the immune system and its related molecules are important players in persistent pain and thus possess immense therapeutic potential. Unsurprisingly, the identification of novel immune-related targets has attracted the interest of many. Here we have explored the role of an orphan receptor, G-protein receptor 84 (GPR84), that was identified originally using an expressed sequence tag data mining strategy (Wittenberger et al., 2001). GPR84 consists of a generic heptahelical structure and is thought to belong to the rhodopsin superfamily, with little similarity to other known receptors. Expression analysis revealed that human and mouse GPR84 mRNA is found predominantly in hematopoietic tissues, including bone marrow, lung, spleen, and lymph node (Wittenberger et al., 2001; Wang et al., 2006). Its expression is restricted to peripheral immune cells and microglia in the CNS, and it is upregulated via appropriate immunostimulation [such as lipopolysaccharide (LPS) or TNF exposure; Wang et al., 2006; Bouchard et al., 2007; Lattin et al., 2008]. Although GPR84 was discovered well over a decade ago, very little is known about its functional role. So far, functional analyses have suggested that it is a free fatty acid (FFA) sensing GPCR that couples primarily to the Bordetella pertussis toxin-sensitive Gral pathway (Wang et al., 2006; Suzuki et al., 2013). In particular, FFAs with medium carbon chain lengths of C9–C14 have shown efficacy in heterologous expression systems, but the endogenous ligand has yet to be identified. Several groups have postulated an immunomodulatory role that coincides with its restricted immune cell expression. It has been reported that GPR84 mediates chemotaxis and the release of TNF and IL-12 from macrophages and IL-8/chemokine ligand 8 from granulocytes (Wang et al., 2006; Suzuki et al., 2013). IL-12 plays a key role in promoting T-helper 1 (Th1)-driven immunity while inhibiting Th2 anti-inflammatory responses. Therefore, it is plausible
that GPR84 is involved in regulating Th1 differentiation to promote an inflammatory response. Interestingly, these findings were consistent with augmented Th2 cytokine production in GPR84 null T cells (Venkataraman and Kuo, 2005). Furthermore, Bouchard et al. (2007) demonstrated that GPR84 mRNA is strikingly upregulated in cortical and spinal microglia in a model of endotoxemia and experimental autoimmune encephalomyelitis (EAE). Together, these findings are suggestive of an immunoregulatory and neuroinflammatory function.

Despite a lack of evidence of a role in nociceptive transmission, the upregulation of GPR84 mRNA has been observed in clinically relevant animal models of diabesity and EAE, which feature pain-associated pathologies (Bouchard et al., 2007; Tomlinson and Gardiner, 2008; Nagasaki et al., 2012; Khan et al., 2014). Moreover, its role in promoting a proinflammatory immune response and the release of cytokines, many of which can directly or indirectly modulate pain pathways (Kiguchi et al., 2012), supports the notion that GPR84 is a promising new target in the field.

Here we used GPR84 null mice to examine pain behaviors in a model of peripheral nerve injury. We focused on changes in the response of spinal microglia and peripheral macrophages with the aim of elucidating the contribution of GPR84 to neuropathic pain states.

Materials and Methods

**Experimental animals.** GPR84 (GenBank accession number NM_030720, Ensembl identification number ENSMUSG00000083234) KO mice were provided by Deltagen under a GlaxoSmithKline license agreement. Targeting replaced 257 bp of coding sequence with an IRES–LacZ–poly(A) expression cassette and a positive selection cassette that contains the neomycin phosphotransferase gene driven by the PGK promoter (Neo).

The insertion of the LacZ IRES-LacZ introduces a premature translational stop signal that deletes the first three predicted transmembrane domain sequences. Disruption of the GPR84 gene was confirmed using PCR and standard agarose gel electrophoresis using the following primers: gene specific (endogenous), 5'-ACACGTCAAGTGGCAGCCTCCTCGT-3'; gene specific (targeted, endogenous), 5'-TCTCTAGAGCATAATGAGACA-GAGGGTG-3'; and Neo (targeted), 5'-GAGGAGTCTTCTGAGGAGATGCTAC-3'.

Mice forming the initial breeding pairs were supplied by GlaxoSmithKline, which consisted of heterozygous (HET) F1 offspring from WT and KO breeding. HET pairs were bred in-house from 8 weeks old to produce litters of mixed genotypes according to Mendelian genetics. Mice were housed individually or in groups in standard environmental conditions (12 h light/dark cycle) with ad libitum access to food and water. Experiments were conducted in a blocked design on randomly selected, mixed sex- and age-matched WT and KO mice weighing 20–30 g (7–14 weeks old). HETs were only used for breeding. Animal husbandry and experiments were performed in a nonsterile housing environment in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986. For all studies, the experimenter was blinded to genotype and treatment.

**Mechanical withdrawal threshold.** Static mechanical thresholds of alert and unrestrained mice were examined via von Frey hair application (0.008–1 g; Touch Test; Stoelting) to the plantar surface of the hindpaw using the “up–down” method (Chaplan et al., 1994). Before testing, mice were acclimatized individually for 1 h in acrylic testing cubicles (8 × 5 × 10 cm) on an elevated wire mesh floor to enable access to the lateral paw surface. Placement in testing cubicles was selected at random for each testing day. Briefly, calibrated von Frey hairs were applied in an alternate manner to the left or right hindpaw, starting with the 0.6 g filament. The flexible nylon hair was applied so that the fiber was bent for 3 s or until a paw-withdrawal reflex occurred. A positive withdrawal response is followed by a lower force hair and vice versa for a negative response until a change in behavior occurs. Using this up–down sequence, four subsequent hairs were assessed and the 50% paw-withdrawal threshold (PWT) was calculated according to the method described by Dixon (1980).
were cut on the cryostat at 20 μm thickness and subsequently thaw mounted onto SuperFrost Plus microscope slides (VWR). After drying, 7 d post-PNL or sham surgery spinal cord sections were incubated overnight with primary antibody solution for phosphorylated p38 MAPK (p-p38; rabbit anti-p-p38; 1:100; Sigma) and visualized with extrAvidin–FITC after two stages of signal amplification with avidin–biotin complex (Vector Laboratories) and biotinyl tyramide (PerkinElmer Life and Analytical Sciences) as shown previously (Clark et al., 2006). The sections were then incubated overnight with the second primary antibody, raised against rabbit anti-Iba1 (1:1000; Wako Chemicals). Spinal cord (21 d) and sciatic nerve sections were incubated with Iba1 and rat anti-cluster of differentiation 45 (CD45; 1:500; R&D Systems). Subsequently, sections were incubated with the appropriate secondary antibody solution for 2 h (1:1000; IgG-conjugated Alexa Fluor 488 or 546; Invitrogen). All antibodies were prepared in PBS supplemented with 0.1% Triton X-100 (VWR) and 0.2% sodium azide (Sigma). Slides were coverslipped with Vectashield Mounting Medium containing DAPI (Vector Laboratories), and images were captured using a Axiosplan microscope (Zeiss).

Quantification of immunoreactivity. In spinal cord sections, analysis of p-p38 and Iba1 immunoreactivity was performed by counting the number of positive profiles within three fixed 4 × 10^5 μm^2 boxes in the lateral, central, and medial areas of the dorsal horn, using the nuclear marker DAPI to assist in determining positive cells, as described previously (Clark et al., 2007). A mean value was obtained for both the ipsilateral and contralateral dorsal horns. In sciatic nerve sections, two boxes of 4 × 10^5 μm^2 area were placed proximal to the nerve lesion and 1 mm from the epicenter. For analysis of contralateral nerve sections, two boxes were placed randomly along the nerve. The number of Iba1- and CD45-positive cells was counted within the boxes, and a mean value was obtained. Again DAPI was used to assist in the identification of positive cell profiles. Throughout the quantification process, a minimum of three sections per animal was assessed, and scoring was performed blind to genotypic and treatment.

Bio-Gel elicited peritoneal macrophage cell culture and stimulation. Adult GPR84 WT and KO mice were given an intraperitoneal injection (1 ml) of Bio-Gel P-100 2% polyacrylamide beads (Bio-Rad). Four days later, mice were killed via cervical dislocation, and the layer of skin covering the peritoneum was wiped with 70% ethanol. A total volume of 20 ml of sterile cold PBS (Invitrogen) containing EDTA (3 mM; Invitrogen) was injected into the peritoneal cavity using a 25 gauge needle. After gentle massaging, the buffer was retrieved in 14 ml Falcon tubes, filtered to remove the polyacrylamide beads, and spun to obtain a pellet. Cells were then resuspended and plated in cAMP-Screen Direct precoated 96-well assay plates (Invitrogen) at a density of 1.5 × 10^5 cells per well for the assessment of cAMP production. For mRNA analysis, peritoneal macrophages were collected, resuspended carefully and Bio-Gel in cAMP-Screen Direct precoated 96-well assay plates (Invitrogen) at a density of 1.0 × 10^5 cells per well to assess cAMP production. Twenty-four hours later, the medium was replaced with FBS-free medium for 2 h, followed by 3 h of LPS stimulation (1 μg/ml Sigma). The culture medium of control wells was replaced with fresh FBS-free medium without subsequent stimulation.

RNA extraction and cDNA synthesis. On days 7 or 21 after PNL or sham surgery, mice were terminally anesthetized with sodium pentobarbital (0.2 g/ml; l.p.; Euthatal; Merial Animal Health). The lumbar region of the spinal cord was dissected, separated into the ipsilateral and contralateral sides, and placed into separate RNase free 1.5 ml Eppendorf tubes. The ipsilateral and contralateral sciatic nerves of ~1 cm in length were also collected and stored. The collected tissue was immediately snap frozen in liquid nitrogen and stored at −80°C for additional processing. RNA was extracted via homogenizing the tissue samples using a hybrid method of phenol extraction (TRIzol; Invitrogen) and column purification (RNeasy; Qiagen). After purification, the RNA was eluted using RNase-free water, and its concentration and purity were estimated using a NanoDrop ND-100 Spectrophotometer (Thermo Fisher Scientific). All 260:280 absorbance ratios were in the range of 1.96−2.15. During RNA isolation, samples were also treated with DNase (Qiagen) to prevent genomic contamination. RNA integrity was confirmed with a RNA 6000 Nano Chip Bioanalyzer (Agilent Technologies). cDNA was subsequently synthesized from RNA using the SuperScript II reverse transcriptase kit (Invitrogen) according to the guidelines of the manufacturer.

After LPS stimulation of cultured peritoneal macrophages, cells were homogenized by removing the media and directly adding TRIzol to the well. RNA was extracted, and cDNA was synthesized as described above.

Taqman array setup and quantitative real-time PCR. Taqman PCR array cards were custom designed using the Applied Biosystems website (http://www.appliedbiosystems.com). The cards use micro-fluidic technology, comprising 384 wells and four sets of 96 different primer/probe pairs against specific genes within the mouse genome, including four reference genes: glyceraldehyde-3-phosphate dehydrogenase, 18S ribosomal RNA, β-actin, and hypoxanthine phosphoribosyltransferase. Spinal cord and sciatic nerve cDNA samples from 7 and 21 d post-PNL or sham surgery and control or LPS-stimulated macrophages were diluted and added in a 1:1 ratio to Taqman universal PCR master mix (Applied Biosystems; contains DNA Taq polymerase and dNTPs). DNase-free water was added to the sample mix, producing a final (cDNA) of 2 ng/μl in a total volume of 100 μl. The sample mix was loaded into the appropriate port, and the cards were centrifuged so that 1 μl was channeled into each well. Cards were then sealed and placed into a 7900 HT Fast Real-Time PCR system (Applied Biosystems), and cDNA samples underwent 40 amplification cycles. For each sample, changes in gene expression were calculated using the Delta Delta cycling time (ΔΔCT) method as described previously (Schmittgen and Livak, 2008) and normalized against four reference genes with the R package ReadPCR and NormqPCR (Perkins et al., 2012). Transcripts with undetermined values in >50% of the samples were assigned an average default CT value of 38. When this occurred in both PNL and sham control and LPS-stimulated sample groups, no fold change (FC) value was calculated (FC = treatment/control). Transcripts that were undetermined in <50% of samples obtained an average CT value based on the remaining data values. cAMP-screen direct chemiluminescent ELISA. GPR84 WT and KO Bio-Gel elicited peritoneal macrophages (B-GEMPs) or bone marrow-derived macrophages (BMDMs) were harvested as described above and plated in cAMP-Screen Direct precoated 96-well assay plates (Invitrogen) at a density of 1.0−1.5 × 10^5 cells per well. Two hours later, the cells were washed, replenished with fresh DMEM (Invitrogen), and left overnight to settle. All cell stimulation protocols were performed 24 h later and done in FBS-free DMEM (Sigma) at 37°C. WT and KO cells were incubated for 20 min with 50 μM forskolin (FSK; R&D Systems), and control wells were incubated in fresh media containing 0.002% ethanol. Cells that underwent LPS stimulation were incubated with 1 μg/ml LPS (Sigma) for 3 h before FSK stimulation. After the stimulation procedure, the assay was terminated, and samples were processed according to the guidelines of the manufacturer (Invitrogen). Subsequently, the luminescence signal for each well was measured using a standard luminometer (1 s/well), and the cAMP concentration was calculated via extrapolation from a standard curve.
Data and statistical analysis. All data were analyzed using SigmaPlot 12.3 and SigmaStat software. For single comparisons between two groups, a paired Student’s t test was applied (behavioral data). For multiple comparisons, one-way (immunohistochemical data) or two-way (behavioral data) ANOVA was used, followed by Student–Newman–Keuls (SNK) post hoc test to determine individual group differences. For the Taqman mouse PCR array card data, two-sided Welch’s t tests were run in the R program on the ΔΔCT values. The p values were adjusted using the false discovery rate (FDR) to correct for multiple hypothesis testing, as described previously (Benjamini et al., 2001). Nonparametric tests were applied when the data were not normally distributed, and a Kruskal–Wallis one-way ANOVA on ranks was used, followed by Tukey’s method. In all cases, the data are presented as the mean ± SEM, and p < 0.05 was set as the statistical significance level.

Results
GPR84 KO mice have normal acute pain thresholds, but neuropathic pain hypersensitivity is absent
We first investigated whether GPR84 function affects acute pain, and WT and KO mice were assessed behaviorally after acute peripheral application of a range of mechanical and thermal stimuli (Fig. 1). KO mice exhibited normal thermal pain thresholds to varying levels of intensity applied to the hindpaw or tail (Fig. 1A–E) compared with WT littermates. KO mice also exhibited normal mechanical thresholds of low and high intensity (Fig. 1F,G) and showed no deficits in locomotor function (Fig. 1H).

To determine whether GPR84 plays a role in chronic pain, we tested mechanical and thermal thresholds of WT and KO mice after PNL or sham surgery. It is well established that peripheral nerve injury results in the development of mechanical and thermal hypersensitivity in the ipsilateral hindpaw. Accordingly, nerve injured WT mice showed an average reduction of 68.8% in mechanical thresholds from baseline that was present on day 4 and persisted until day 21 (Fig. 2A). WT mice also exhibited an increase in thermal sensitivity, with an average reduction of 25.4% in thresholds from baseline over the 21 testing days (Fig. 2B). In contrast, nerve injured KO mice did not develop mechanical (Fig. 2C) or thermal (Fig. 2D) hypersensitivity over the 21 testing days, and thresholds did not drop from baseline or differ from KO sham controls at any point. For clarity, genotype data are presented separately, but statistical analysis was conducted on all four experimental groups. Together, these data indicate that GPR84 deletion impairs the development and persistence of neuropathic pain hypersensitivity, but under normal physiological conditions, GPR84 is not involved in acute nociception.

GPR84 does not modulate microglial responses under neuropathic conditions
Since microglia play a key role in the initiation of pain-associated behaviors and GPR84 is expressed exclusively on these cells in the
CNS (Bouchard et al., 2007), we examined the microglial phenotype to elucidate whether deletion of GPR84 alters nerve injury-induced microgliosis. Quantification of Iba1 immunoreactivity at 7 d after PNL revealed that both genotypes showed a 3.2-fold increase in Iba1-positive cells in the ipsilateral dorsal horn (WT PNL, 21.1 ± 0.7; KO PNL, 21.6 ± 2.4) compared with sham controls (WT, 6.6 ± 2.0; KO, 6.7 ± 0.7; Fig. 3A, B). This change persisted at 21 d after PNL for both genotypes, with a 1.8-fold increase compared with sham (WT PNL, 9.3 ± 0.7; KO PNL, 11.1 ± 0.8 vs WT, 5.3 ± 0.6; KO, 6.1 ± 0.9; Fig. 3D, E). Notably, at both time points, KO microglia exhibited typical de-ramified and amoeboid morphology in response to injury to that seen in the WT.

We also assessed whether GPR84 deletion affects the activation of microglial cells as revealed by p-p38 MAPK, a key kinase in nociceptive pathways (Ji and Suter, 2007; Ji et al., 2009). At day 7, WT and KO mice showed a 3.4- and 4.1-fold increase in p-p38 positive cells, respectively, in the ipsilateral dorsal horn (WT PNL, 20.4 ± 2.1; KO PNL, 18.6 ± 3.7) compared with sham controls (WT, 6.0 ± 2.3; KO, 4.5 ± 1.3; Fig. 3A, C), and there were no significant differences between genotypes. In summary, GPR84 does not play a role in modulating microglial numbers or activation via Iba1 and p-p38 markers, respectively, in response to peripheral neuropathy.

GPR84 activation promotes a proinflammatory macrophage phenotype
As we found no evidence of an altered microglia response in association with the KO behavioral phenotype, we sought to examine the possible contribution of peripheral macrophages. Macrophages are the key phagocytic immune cell of the PNS and are also reported to play a role in nerve injury-induced behavioral hypersensitivity (Myers et al., 1996; Liu et al., 2000; Barclay et al., 2007). To investigate whether deletion of GPR84 may alter the peripheral inflammatory response to nerve damage mediated by infiltrating macrophage cells, longitudinal sciatic nerve sections containing the injury site were immunostained for Iba1 and CD45 at 7 d after PNL. Positive cell profiles costained with DAPI were counted proximal to the lesion site and 1 mm from the epicenter as illustrated in Figure 4I. Quantification of immunoreactivity revealed that, in WT and KO mice, there was a 93.4 and 92.8% increase in Iba1-positive cells, respectively, compared with contralateral controls (WT ipsilateral, 9.3 ± 0.7; KO ipsilateral, 11.1 ± 0.8 vs WT, 5.3 ± 0.6; KO, 6.1 ± 0.9; Fig. 3D, E). Notably, at both time points, KO microglia exhibited typical de-ramified and amoeboid morphology in response to injury to that seen in the WT.

We also assessed whether GPR84 deletion affects the activation of microglial cells as revealed by p-p38 MAPK, a key kinase in nociceptive pathways (Ji and Suter, 2007; Ji et al., 2009). At day 7, WT and KO mice showed a 3.4- and 4.1-fold increase in p-p38 positive cells, respectively, in the ipsilateral dorsal horn (WT PNL, 20.4 ± 2.1; KO PNL, 18.6 ± 3.7) compared with sham controls (WT, 6.0 ± 2.3; KO, 4.5 ± 1.3; Fig. 3A, C), and there were no significant differences between genotypes. In summary, GPR84 does not play a role in modulating microglial numbers or activation via Iba1 and p-p38 markers, respectively, in response to peripheral neuropathy.

GPR84 activation promotes a proinflammatory macrophage phenotype
As we found no evidence of an altered microglia response in association with the KO behavioral phenotype, we sought to examine the possible contribution of peripheral macrophages. Macrophages are the key phagocytic immune cell of the PNS and are also reported to play a role in nerve injury-induced behavioral hypersensitivity (Myers et al., 1996; Liu et al., 2000; Barclay et al., 2007). To investigate whether deletion of GPR84 may alter the peripheral inflammatory response to nerve damage mediated by infiltrating macrophage cells, longitudinal sciatic nerve sections containing the injury site were immunostained for Iba1 and CD45 at 7 d after PNL. Positive cell profiles costained with DAPI were counted proximal to the lesion site and 1 mm from the epicenter as illustrated in Figure 4I. Quantification of immunoreactivity revealed that, in WT and KO mice, there was a 93.4 and 92.8% increase in Iba1-positive cells, respectively, compared with contralateral controls (WT ipsilateral, 9.3 ± 0.7; KO ipsilateral, 11.1 ± 0.8 vs WT, 5.3 ± 0.6; KO, 6.1 ± 0.9; Fig. 3D, E). Notably, at both time points, KO microglia exhibited typical de-ramified and amoeboid morphology in response to injury to that seen in the WT.

We also assessed whether GPR84 deletion affects the activation of microglial cells as revealed by p-p38 MAPK, a key kinase in nociceptive pathways (Ji and Suter, 2007; Ji et al., 2009). At day 7, WT and KO mice showed a 3.4- and 4.1-fold increase in p-p38 positive cells, respectively, in the ipsilateral dorsal horn (WT PNL, 20.4 ± 2.1; KO PNL, 18.6 ± 3.7) compared with sham controls (WT, 6.0 ± 2.3; KO, 4.5 ± 1.3; Fig. 3A, C), and there were no significant differences between genotypes. In summary, GPR84 does not play a role in modulating microglial numbers or activation via Iba1 and p-p38 markers, respectively, in response to peripheral neuropathy.
does not play a role in regulating the infiltration of monocytes or the local proliferation and migration of resident macrophages to the injury site.

We next wanted to determine whether deletion of GPR84 correlates with an altered nerve injury-induced inflammatory mediator expression. Here we used high-throughput custom-made Taqman array cards to profile the transcriptional regulation of a range of immune-related genes (cytokines, chemokines, and growth factors) in the nerve and spinal cord of WT and KO mice. We found that a number of genes were differentially regulated between the genotypes (data not shown), several of which were of particular interest to us, including arginase-1 (Arg-1), IL-10, and Gpr84 itself. Genes of interest were identified via implementing strict threshold criteria. This included an FC threshold of ≥2 so that genes with marginal expression changes as a result of noise were excluded. An FC ratio (KO FC/WT FC) of ≥1.5 was also set to omit genes that were not transcriptionally regulated by GPR84. Together, these criteria enabled the identification of genes that were considerably differentially regulated between genotypes.

In agreement with our hypothesis that GPR84 is a valid target in chronic pain, its expression was upregulated in the sciatic nerve and spinal cord of neuropathic WT mice at days 7 and 21 compared with sham controls; however, this was only significant
in the nerve at day 7 (36.7 ± 9.4; Fig. 4K). Interestingly, Arg-1, a marker associated specifically with alternatively activated macrophages, was among the top upregulated genes in the sciatic nerves of KO mice 7 d after PNL compared with WT controls (WT, 3.8 ± 0.4; KO, 21.2 ± 5.6; Fig. 4L). Furthermore, the expression of the anti-inflammatory cytokine IL-10 was more greatly induced in the injured nerves of KOs than WTs (WT, 1.7 ± 0.2; KO, 6.9 ± 3.2; Fig. 4M). These results indicate that, although the number of monocytes/macrophages in the injured sciatic nerve does not differ between genotypes, it is possible that GPR84 regulates the activation state of these cells instead. In addition, GPR84 mRNA upregulation was greater in the nerve than the spinal cord of WT mice, and there were no differences in microgliosis between genotypes, suggesting that GPR84-mediated signaling may be more important in the periphery. Based on this evidence and the documented role of macrophages in models of inflammation and

Figure 4. After injury, GPR84 KO mice exhibit normal peripheral macrophage recruitment but elevated anti-inflammatory marker expression in the sciatic nerve. There was a significant increase in Iba1- and CD45-positive cells in the ipsilateral (ipsi) sciatic nerve 7 d after PNL in GPR84 WT (E, G) and KO (F, H) mice compared with contralateral (contra) controls (A, C and B, D, respectively; quantified in J). There were no significant differences between genotypes. Longitudinal sections of nerve were counted, proximal to the nerve injury and 1 mm from the epicenter as illustrated in I. Scale bar, 1000 μm. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 versus contralateral, one-way ANOVA with SNK post hoc test, n = 3. Scale bar, 200 μm. Transcriptional analysis revealed an induction of GPR84 expression in WT sciatic nerve and spinal cord at 7 and 21 d after PNL compared with sham (K). In the sciatic nerve of KO mice 7 d after PNL, there was a greater induction of Arg-1 (L) and IL-10 (M) compared with WT littermates. Changes in mRNA expression are normalized to reference genes. Data are presented as mean ± SEM. **p < 0.01 versus sham; ***p < 0.001 versus WT PNL, t test with FDR for multiple testing correction, n = 4.
traumatic nerve injury-induced pain, we then tested whether GPR84 deletion impairs the ability of macrophages to launch an inflammatory response.

As before, we used custom-made Taqman array cards to analyze the relative expression of a range of mediators in peritoneal macrophages after a potent immune stimulus. LPS stimulation of cultured macrophages increases cytokine synthesis in a Toll-like receptor-4 (TLR4) dependent manner, which is a key molecule involved in generating responses to pathogen-associated molecular patterns (PAMPs). PAMPs, such as HSP60 and HSP70, necrotic cells, and components of the extracellular matrix (ECM) are abundantly found at sites of injury. These factors activate TLR signaling and nuclear factor-κB (NF-κB)-mediated transcription of many proinflammatory mediators (Nguyen et al., 2002; Willis et al., 2005). Accordingly, application of LPS to the injured sciatic nerve enhances the recruitment of macrophages and the process of Wallerian degeneration (Boivin et al., 2007), whereas deletion of TLR4 attenuates pain-associated behaviors (Tanga et al., 2005). Based on this evidence, we believe that our in vitro paradigm was a relevant representation of the in vivo situation and would enable us to examine genotypic-dependent differences in the macrophage response.

Among the 92 immune-related genes tested after LPS exposure, several proinflammatory mediators associated with nociceptive signaling showed a greater upregulation in WT than KO cells. These were IL-1 (WT, 155.4 ± 51.3; KO, 123.8 ± 50), IL-6 (WT, 570.4 ± 67.2; KO, 198.6 ± 53.6), Tnf-α (WT, 74.5 ± 7.6; KO, 51.5 ± 7.5), prostaglandin E synthase 2 (Ptges2; WT, 408.2 ± 80.6; KO, 237.1 ± 99.4), nitric oxide synthase 2 (Nos2; WT, 85.8 ± 22.7; KO, 26.3 ± 7.5), Il-12b (WT, 81.3 ± 19.3; KO, 29.1 ± 7.9), chemokine (C-C motif) ligand 2 (Ccl2; WT, 37.9 ± 6.7; KO, 18.3 ± 3.1), and Ccl3 (WT, 101.4 ± 9.3; KO, 47.3 ± 5.7). Conversely, anti-inflammatory Il-10 was more greatly induced in the KO (WT, 27.2 ± 20.9; KO, 44.0 ± 37.1; Fig. 5A, B). LPS stimulation also increased Gpr84 expression in WT cells (3.3 ± 0.7) and was undetectable in the KO (Fig. 5A, B). These findings suggest that GPR84 regulates the release of a subset of proinflammatory mediators under neuropathic conditions. Therefore, it is plausible that the painless KO phenotype is attributable to a reduced capacity of peripheral macrophages to launch an inflammatory response.

In light of our transcriptional data, we wanted to ascertain whether KO macrophages are immunosuppressed by examining the synthesis of cAMP under FSK- and LPS-stimulated condi-
tions. Elevated intracellular cAMP has been shown to suppress innate immune functions, such as phagocytosis, microbe killing, and production of proinflammatory mediators, but promote the release of anti-inflammatory mediators (Bourne et al., 1974; Seretzani et al., 2008; Peters-Golden, 2009). We demonstrated that, in two separate populations of macrophages (B-GEPMs and BMDMs), KO cells generated greater levels of intracellular cAMP than WT cells compared with control (B-GEPMs WT, 121.2 ± 6.4 fmol/ml vs KO, 342.5 ± 37.9 fmol/ml; BMDMs WT, 1960.3 ± 559.8 fmol/ml vs KO, 6995.1 ± 5225.3 fmol/ml; Fig. 5C). This intriguing greater capacity of KO macrophages to synthesize cAMP was also maintained under LPS-stimulated conditions, which is known to reduce cAMP production (BMDMs: WT, 2965.9 ± 1425.3 fmol/ml; KO, 6791.5 ± 3615.1 fmol/ml; Fig. 5C). In accordance with the literature, these findings support that GPR84 is coupled to the inhibitory Gαi/o family of G-proteins (Wang et al., 2006) and is essential for downregulating cAMP in peripheral macrophages to promote a proinflammatory response.

Discussion
To the best of our knowledge, this is the first study to demonstrate a critical role of GPR84 in experimental neuropathic pain. Consistent with this observation, GPR84 mRNA expression was increased in the sciatic nerve and spinal cord after PNI, and its deletion abolished the associated mechanical and thermal behavioral hypersensitivity in mice. Given that GPR84 is expressed selectively in immune cells (Wang et al., 2006; Bouchard et al., 2007), we studied microglia and macrophage responses to neuropathy in the presence and absence of this receptor. Interestingly, we did not detect any differences in spinal microglial responses or macrophage numbers in the sciatic nerve between genotypes. However, despite no deficit in macrophage recruitment, we observed a striking transcriptional upregulation of the anti-inflammatory macrophage marker Arg-1 and cytokine IL-10 in injured KO nerves compared with WT controls.

Arg-1 is upregulated in alternatively activated macrophages and metabolizes l-arginine into l-ornithine and urea. Due to its higher affinity for arginine, it outcompetes inducible NOS (iNOS), which metabolizes l-arginine in classically activated cells (Kreider et al., 2007). Subsequently, ornithine amino-transerase synthesizes proline from ornithine, a substrate crucial in collagen production, whilst ornithine decarboxylase generates polyamines that are involved in cellular proliferation. Together, these pathways contribute to growth, differentiation, and ECM formation. Thus, alternatively activated macrophages are involved in functions related to host defense, repair/wound healing and the dampening down of harmful inflammation. In contrast, classically activated macrophages are associated with an upregulation of iNOS and the production of NO and l-citrulline. Due to its higher affinity for arginine, it outcompetes inducible NOS, which metabolizes l-arginine into l-ornithine and urea. Arg-1 is upregulated in alternatively activated macrophages and metabolizes l-arginine into l-ornithine and urea. Due to its higher affinity for arginine, it outcompetes inducible NOS (iNOS), which metabolizes l-arginine in classically activated cells (Kreider et al., 2007). Subsequently, ornithine amino-transerase synthesizes proline from ornithine, a substrate crucial in collagen production, whilst ornithine decarboxylase generates polyamines that are involved in cellular proliferation. Together, these pathways contribute to growth, differentiation, and ECM formation. Thus, alternatively activated macrophages are involved in functions related to host defense, repair/wound healing and the dampening down of harmful inflammation. In contrast, classically activated macrophages are associated with an upregulation of iNOS and the production of NO and l-citrulline. Subsequently, ornithine amino-transerase synthesizes proline from ornithine, a substrate crucial in collagen production, whilst ornithine decarboxylase generates polyamines that are involved in cellular proliferation.

In animal models of nerve injury, the infiltration of classically activated macrophages (iNOS+/ARG+) into the sciatic nerve has been reported as soon as day 1 (Komori et al., 2011). Treatment with anti-inflammatory cytokines, such as IL-4 or TGF-β, attenuates pain-associated behaviors via the modulation of macrophages. For example, in one study, perineural administration of TGF-β decreased macrophage infiltration, which correlated with reduced behavioral hypersensitivity (Echeverry et al., 2013). Likewise, the analgesic effects of IL-4 coincided with a shift in the macrophage phenotype as indicated by upregulated phosphorylated signal transducer and activator of transcription 6 and CD206 expression (Kiguchi et al., 2015). The beneficial effects of inhibiting classical activation while promoting alternative activation have also been demonstrated in models of post-incisional pain and experimental autoimmune neuritis (EAN). One group showed that local morphine administration into the incised sites alleviated pain attributable to increased infiltration of wound healing F4/80+ CD206+ macrophages (Godai et al., 2014). Similarly, genetic deletion of TNF-α or treatment with compound A, a plant-derived glucocorticoid receptor ligand, in EAN mice correlated with decreased severity scores and progression of mechanical allodynia. This was found to be a result of increased
numbers of alternatively activated ED2⁺ (CD163) macrophages in the sciatic nerve (Zhang et al., 2009, 2012). In agreement with these studies, our results suggest that the absence of pain behaviors in the KO concurred with an alternatively activated macrophage phenotype. Unsurprisingly, this notion is not limited to chronic pain because classically activated macrophages have been implicated in numerous other diseases, such as obesity and diabetes (Bastard et al., 2006; Mosser and Edwards, 2008). Therefore, selective targeting of these cells poses to be a viable option for the therapeutic treatment of various human diseases.

An interesting observation from our research was the significant microgliosis in the spinal cord of injured KO mice, despite the absence of pain behaviors. GPR84 is expressed exclusively on spinal microglia, and there is an independent body of evidence supporting the contribution of these cells to chronic pain pathways (Xanthos and Sandkühler, 2014). Nevertheless, the number of microglia in the dorsal horn did not differ in GPR84 null mice compared with WT littermates, nor could we see any difference in the degree of p-p38, known to be critical for microglial–neuron interactions under neuropathic conditions. Disassociation between microglia and their contribution to behavioral hypersensitivity in animal models of peripheral neuropathy have been documented previously (Colburn et al., 1997; Hashizume et al., 2000; Winkelstein and DeLeo, 2002; Shi et al., 2011). However, although we were unable to identify microglial involvement, our analysis was limited to gross immunophenotypic differences; thus, we cannot rule out a potential contribution of these cells. Furthermore, in contrast to our findings, a recent study demonstrated a beneficial role of GPR84 in a mouse model of Alzheimer’s disease (AD). The authors showed that GPR84 KO mice exhibited accelerated cognitive decline that correlated with reduced microgliosis, hence indicating that microglial recruitment is protective in amyloid pathology (Audoy-Rémus et al., 2015). Evidence of microgliosis has been demonstrated in a number of different neurodegenerative diseases (Parkinson’s disease, multiple sclerosis, and amyotrophic laterals sclerosis) including AD, as well as other types of neurological disorders (stroke, inflammation, and epilepsy). This response is generally believed to have detrimental effects, and it has not been until recently that more studies have begun to take into account both the harmful and protective effects of these multitalented cells. As a result, it remains unclear whether microglia activation is a causative (“bad for”) or reactive (“good for”) factor in disease pathology.

Currently, the signaling pathway of GPR84 is unknown. In any case, considering that its expression is highly regulated by LPS and other stimulators of the NF-kB pathway (IL-1β and TNF-α; Bouchard et al., 2007), it is plausible that it shares signaling pathways similar to that of chemokine receptors. The endogenous ligand also remains unknown, but of course, it too is likely to have an interesting biology and be important in pain processing. Some data suggest that short-chain fatty acids can activate the receptor, and these may turn out to be the endogenous ligand. Whatever the actual ligand is, we postulate that, under pathological conditions, GPR84 can be activated to evoke the release of proinflammatory mediators that contribute to pro-nociceptive signaling.

In conclusion, our findings point toward a peripherally driven role for GPR84 signaling in the context of neuropathic pain. The ability of GPR84 to induce pain hypersensitivity may provide scope for the modulation of peripheral macrophage activation and hence the alleviation of pain. We believe that the specific immune cell expression and proinflammatory profile warrants GPR84 as an exciting, new, non-neuronal target for the treatment of chronic pain.

References


Bastard JP, Maichi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12. Medline


Khan N, Woodruff TM, Smith MT (2014) Establishment and characterization of an optimized mouse model of multiple sclerosis-induced